Business Wire

The Estée Lauder Companies Announces New Leadership Appointments in Asia/Pacific and Elevation of China

Share

Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced the following updates to its Asia/Pacific leadership, which are effective February 1, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006407/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ELC Appoints Joy Fan as President and CEO, China (Photo: Business Wire)

  • Joy Fan will be promoted to President and CEO, China. She will report directly to Peter Jueptner in his new role as President, International, and she will remain a member of ELC’s Executive Leadership Team.
  • Following the recent announcement that Mark Loomis, currently President, Asia/Pacific, will be taking on a new role as President, North America, Matthew Growdon, currently General Manager, Japan, will be promoted to Senior Vice President and General Manager, Asia/Pacific, also reporting directly to Peter. He will become a member of the Executive Leadership Team, leading all markets in Asia/Pacific, excluding mainland China.1
  • Mainland China will be elevated to report directly into the International organization.

“This important evolution in our regional enterprise structure reflects our dedication to leveraging the unique talents, local expertise, and proven track records of internally-trained leaders across the organization. As we continue to elevate our commitment to China and Chinese consumers, these updates will also reinforce our focus on Asia/Pacific to realize future business growth,” said Fabrizio Freda, President and Chief Executive Officer. “We are proud to elevate Joy and Matthew, two seasoned and globally-minded strategic leaders at the helm of our China and Asia/Pacific businesses.”

“This business evolution will further enable our regions to lead in an increasingly complex and competitive beauty landscape,” said Cedric Prouvé, Group President, International. “I have every confidence in Joy’s and Matthew’s strong leadership of our talented China and Asia/Pacific teams and know they will take our business to even greater heights as they step into their new roles.”

Please read additional details about the elevation of China and Joy’s and Matthew’s respective appointments below.

The Elevation of China and Promotion of Joy Fan to President and CEO, China

China is one of the most dynamic markets globally for prestige beauty and is strategically significant for the company as a source of deep inspiration for product development, marketing excellence, and consumer insights. The company continues to believe in the long-term growth fundamentals in the market and expects to deepen its commitment to China and Chinese consumers.

Today, the company serves millions of consumers in over 600 cities across mainland China, with incredible potential for the future. Elevating ELC’s China business will enable increased speed, local decision-making, and global collaboration to advance the company’s leadership in this exciting market and to successfully deliver high-quality products and services for the Chinese consumer.

The company is delighted that Joy Fan will assume the new role of President and CEO, China, overseeing the mainland China business. A visionary executive and one of the most respected leaders in the business, she has deep expertise in China, complemented by a global perspective and exceptional brand-building abilities.

In 2012, Joy assumed leadership of the China affiliate, and has since worked with her team to lead its extraordinary growth over the course of just nine years. Her outstanding leadership while spearheading the direct-to-consumer strategy in China has resulted in the growth of multiple brands in ELC’s portfolio and the development of key channels. Additionally, under her guidance, the China affiliate has grown into an industry leader in social media and digital marketing.

Joy has impressively leveraged her outstanding strategic vision, deep understanding of Chinese consumer preferences, and her terrific leadership abilities to successfully drive growth within the market, as well as to elevate the understanding of the Chinese consumer across the enterprise. The strong growth and success of the business in China, under Joy’s leadership, is a testament to her ability to attract and develop a strong China Leadership Team and the best talent across the local organization. Notably, under Joy’s leadership throughout the COVID-19 pandemic, the China affiliate has successfully pivoted to address the changing distribution landscape and evolving consumer preferences to rapidly return the business to positive growth.

In her new role, Joy will continue to be responsible for the company’s long-term growth strategy for China and its vision for the Chinese consumer. The company is proud of the incredibly strong local organization in China that has played a significant role in driving the success in this market, leveraging innovation to recruit and retain new, young consumers, as well as drive repurchase and loyalty.

As ELC expands its scientific presence through its new China Innovation Center in Shanghai, this world-class Innovation Center will create a unique opportunity to grow and build on market and consumer insights to help develop exceptional products to meet and surpass the needs and desires of Chinese consumers. This R&D center and the company’s scientific investments in China are expected to support and inspire the development of the entire prestige beauty industry all over the world. To that end, Joy will play an important role in the development of the China Innovation Center, enabling truly localized innovation.

The company is proud that half of its geographic regional organizations will now be led by women, building upon ELC’s long legacy and commitments to equality and women’s advancement.

Matthew Growdon Appointed Senior Vice President and General Manager, Asia/Pacific

ELC expects Asia/Pacific will continue to be a significant area of strategic focus and future opportunity for the company, as it includes some the largest affiliates globally, high-potential emerging markets, mainly across Southeast Asia, and other key markets of influence. The highly talented and dedicated Asia/Pacific team has done an incredible job of driving the business across the region.

In his new role as Senior Vice President and General Manager, Asia/Pacific, Matthew Growdon will oversee all 12 markets in the region, working closely with affiliate General Managers. With the elevation of China, the Asia/Pacific team, led by Matthew, has an exciting opportunity to further focus its efforts on ELC’s multiple engines of growth throughout the region, including key affiliates that continue to drive the company’s global performance and significant opportunities in emerging markets.

The Asia/Pacific team will continue to focus on strengthening its multiple engines of growth, leveraging new opportunities such as the Dr.Jart+ brand, and building new local capabilities to better serve consumers through its new state of the art manufacturing facility in Japan.

Matthew is a true globalist with nearly 20 years of experience at ELC, which has included broad strategic and global management roles across Asia, Europe, Africa and the United States, as well as for the company’s global brands, including Estée Lauder and TOM FORD BEAUTY. His extensive experience working across geographies and cultures gives him a unique understanding and appreciation for the diverse consumers and channels within each market and especially across the Asia/Pacific landscape.

A strong brand-builder with deep Asia/Pacific expertise, Matthew has led the strategic Japan market in his current role as General Manager, Japan, since January 2020, driving the vision and long-term strategy to deliver against ELC’s ambitions for this influential beauty market. Despite the many challenges from the COVID-19 pandemic, Matthew has led the Japan affiliate’s transformation, including a complete organizational re-design and establishing new capabilities. In addition, he led the channel diversification strategy through a dramatic expansion of the affiliate’s Online presence, the development of consumer data capabilities and strategic partnerships with key retailers.

Highly respected for his inclusive leadership style, Matthew’s experience and strategic focus, combined with the diverse exposure gained from the roles he has held across the globe, give him a unique perspective into the business and will support his ability to successfully lead Asia/Pacific.

A successor for Matthew’s current role will be announced at a later date.

“These well-deserved promotions reflect Joy’s and Matthew’s global expertise, strategic focus and strong abilities to continue advancing our China and Asia/Pacific businesses into the future. I look forward to working closely with them,” said Peter Jueptner, currently President, Europe, the Middle East, and Africa region, who will take on the role of President, International, effective February 1, 2022.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may address our expectations regarding sales, earnings or other future financial performance and liquidity, other performance measures, product introductions, entry into new geographic regions, information technology initiatives, new methods of sale, our long-term strategy, restructuring and other charges and resulting cost savings, and future operations or operating results. Factors that could cause actual results to differ materially from our forward-looking statements are described in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2021. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

1 Mainland China financial performance will continue to be reported in the Asia/Pacific Region.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye